thalidomide has been researched along with Dermatitis Medicamentosa in 39 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Purpose The standard treatment of patients with diffuse large B-cell lymphoma (DLBCL) is rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)." | 9.24 | Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. ( Bosly, A; Bouabdallah, R; Briere, J; Caballero, D; Cabeçadas, J; Casasnovas, RO; Catalano, J; Choufi, B; Cohen, AM; Coiffier, B; Corront, B; Fruchart, C; Gaulard, P; Gomes da Silva, M; Gonzalez, H; Greil, R; Grosicka, A; Haioun, C; Lazarovici, J; Lopez-Guillermo, A; Morschhauser, F; Oberic, L; Perrot, A; Salles, G; Sebban, C; Thieblemont, C; Tilly, H; Trotman, J; van Eygen, K; Van Hoof, A, 2017) |
| "The oral proteasome inhibitor ixazomib is approved in the United States, European Union and other countries, in combination with oral lenalidomide and dexamethasone (Rd), for the treatment of patients with multiple myeloma who have received at least one prior therapy." | 9.24 | Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma. ( Avivi, I; Berg, D; Einsele, H; Esseltine, DL; Gupta, N; Hájek, R; Hari, P; Kumar, S; Liberati, AM; Lin, J; Lonial, S; Ludwig, H; Masszi, T; Mateos, MV; Minnema, MC; Moreau, P; Richardson, PG; Romeril, K; Shustik, C; Spencer, A, 2017) |
| "Thalidomide has been demonstrated to possess antitumor activity in patients with advanced hepatocellular carcinoma (HCC)." | 9.16 | Phase II study of concomitant thalidomide during radiotherapy for hepatocellular carcinoma. ( Ch'ang, HJ; Chang, JS; Chang, YH; Chen, CH; Chen, LT; Hsu, C, 2012) |
| "To improve the outcome of allogeneic stem cell transplantation (allo-SCT) in multiple myeloma as part of first-line treatment, we prospectively investigated the feasibility and efficacy of lenalidomide maintenance." | 9.15 | Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial. ( Bruijnen, CP; Cornelisse, PB; Cornelissen, JJ; Emmelot, M; Huisman, C; Huls, G; Janssen, JJ; Kersten, MJ; Kneppers, E; Lokhorst, HM; Meijer, E; Minnema, MC; Mutis, T; Sonneveld, P; van der Holt, B; Zweegman, S, 2011) |
| "An open-label phase I trial of thalidomide (TL) in 20 patients with neurofibromatosis 1 (NF1) treated symptomatic plexiform neurofibroma (PNF)." | 9.10 | Phase I study of thalidomide for the treatment of plexiform neurofibroma in neurofibromatosis 1. ( Cohen, BH; Gupta, A; Packer, RJ; Phillips, PC; Ruggieri, P, 2003) |
| "Thalidomide has been reported to be an effective agent for treatment of chronic graft-versus-host disease (CGVHD)." | 9.08 | Thalidomide as salvage therapy for chronic graft-versus-host disease. ( Blume, KG; Chao, N; Forman, SJ; Kashyap, A; Long, GD; Margolin, K; Molina, A; Nademanee, A; Negrin, RS; Niland, JC; O'Donnell, MR; Parker, PM; Planas, I; Schmidt, GM; Smith, EP; Snyder, DS; Somlo, G; Spielberger, R; Stein, AS; Stepan, DE; Wilsman, K; Zwingenberger, K, 1995) |
| "Lenalidomide is a potent, novel thalidomide analog that has demonstrated promising clinical activity in patients with relapsed or refractory multiple myeloma (MM)." | 8.84 | Lenalidomide: a new agent for patients with relapsed or refractory multiple myeloma. ( Tariman, JD, 2007) |
| "Lenalidomide and dexamethasone (RD) is a standard of care for relapsed/refractory multiple myeloma (RRMM), but there is limited published data on its efficacy and safety in the "real world" (RW), according to the International Society of Pharmacoeconomics and Outcomes Research definition." | 7.80 | "Real-world" data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group. ( Anagnostopoulos, N; Anargyrou, K; Briasoulis, E; Giannakoulas, N; Hatzimichael, E; Karras, G; Katodritou, E; Kotsopoulou, M; Kyriakou, D; Kyrtsonis, MC; Lalagianni, C; Maniatis, A; Matsouka, P; Michali, E; Papageorgiou, G; Spanoudakis, E; Symeonidis, A; Terpos, E; Tsakiridou, A; Tsionos, K; Vadikolia, C; Zikos, P, 2014) |
| "We here describe a single-institution experience on 40 patients with myelodysplastic syndromes (MDS) consecutively treated with deferasirox at the dose of 10-30 mg/kg/day according to Consensus Guidelines on Iron Chelation Therapy, outside of clinical trials." | 7.78 | Deferasirox treatment for myelodysplastic syndromes: "real-life" efficacy and safety in a single-institution patient population. ( Alimena, G; Breccia, M; Colafigli, G; Federico, V; Finsinger, P; Latagliata, R; Loglisci, G; Petrucci, L; Salaroli, A; Santopietro, M; Serrao, A, 2012) |
| "Factors that affect the response of multiple myeloma patients to thalidomide were evaluated in 40 patients who were not eligible for chemotherapy (untreated: 14, relapse/refractory: 26)." | 7.76 | [Factors affecting the response of thalidomide therapy for patients with multiple myeloma]. ( Agata, M; Ishiyama, M; Kazama, H; Kondo, T; Mori, N; Motoji, T; Oda, T; Okamura, T; Sagawa, K; Sameshima, Y; Shiseki, M; Teramura, M; Yamada, O; Yasunami, T; Yoshinaga, K, 2010) |
| "To examine dermatologic adverse effects of lenalidomide in patients with amyloidosis and multiple myeloma and to determine whether the adverse effects are different when lenalidomide is used alone compared with when it is used in combination with dexamethasone." | 7.73 | Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma. ( Davis, MD; Dispenzieri, A; Rajkumar, SV; Sviggum, HP, 2006) |
| "We report the dermatologic side effects in 87 patients with multiple myeloma enrolled in a comparative, open-label, clinical trial treated with thalidomide alone (50 patients) or thalidomide and dexamethasone (37 patients)." | 7.72 | Dermatologic side effects of thalidomide in patients with multiple myeloma. ( Bouwhuis, S; El-Azhary, RA; Hall, VC; Rajkumar, SV, 2003) |
| "In an open study, oral administration of thalidomide to 7 female patients with classic or definite rheumatoid arthritis, in doses ranging from 6." | 7.67 | Thalidomide. A promising new treatment for rheumatoid arthritis. ( Gutiérrez-Rodríguez, O, 1984) |
| "Sorafenib treatment was effective in two patients who achieved a partial response and a continuous stable disease with duration of 24." | 6.78 | Sorafenib in patients with refractory or recurrent multiple myeloma. ( Goldschmidt, H; Gütgemann, I; Hose, D; Moehler, T; Neben, K; Raab, MS; Schmidt-Wolf, IG; Witzens-Harig, M; Yordanova, A, 2013) |
| "The oral proteasome inhibitor ixazomib is approved in the United States, European Union and other countries, in combination with oral lenalidomide and dexamethasone (Rd), for the treatment of patients with multiple myeloma who have received at least one prior therapy." | 5.24 | Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma. ( Avivi, I; Berg, D; Einsele, H; Esseltine, DL; Gupta, N; Hájek, R; Hari, P; Kumar, S; Liberati, AM; Lin, J; Lonial, S; Ludwig, H; Masszi, T; Mateos, MV; Minnema, MC; Moreau, P; Richardson, PG; Romeril, K; Shustik, C; Spencer, A, 2017) |
| "Purpose The standard treatment of patients with diffuse large B-cell lymphoma (DLBCL) is rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)." | 5.24 | Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. ( Bosly, A; Bouabdallah, R; Briere, J; Caballero, D; Cabeçadas, J; Casasnovas, RO; Catalano, J; Choufi, B; Cohen, AM; Coiffier, B; Corront, B; Fruchart, C; Gaulard, P; Gomes da Silva, M; Gonzalez, H; Greil, R; Grosicka, A; Haioun, C; Lazarovici, J; Lopez-Guillermo, A; Morschhauser, F; Oberic, L; Perrot, A; Salles, G; Sebban, C; Thieblemont, C; Tilly, H; Trotman, J; van Eygen, K; Van Hoof, A, 2017) |
| "Thalidomide has been demonstrated to possess antitumor activity in patients with advanced hepatocellular carcinoma (HCC)." | 5.16 | Phase II study of concomitant thalidomide during radiotherapy for hepatocellular carcinoma. ( Ch'ang, HJ; Chang, JS; Chang, YH; Chen, CH; Chen, LT; Hsu, C, 2012) |
| "To improve the outcome of allogeneic stem cell transplantation (allo-SCT) in multiple myeloma as part of first-line treatment, we prospectively investigated the feasibility and efficacy of lenalidomide maintenance." | 5.15 | Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial. ( Bruijnen, CP; Cornelisse, PB; Cornelissen, JJ; Emmelot, M; Huisman, C; Huls, G; Janssen, JJ; Kersten, MJ; Kneppers, E; Lokhorst, HM; Meijer, E; Minnema, MC; Mutis, T; Sonneveld, P; van der Holt, B; Zweegman, S, 2011) |
| "An open-label phase I trial of thalidomide (TL) in 20 patients with neurofibromatosis 1 (NF1) treated symptomatic plexiform neurofibroma (PNF)." | 5.10 | Phase I study of thalidomide for the treatment of plexiform neurofibroma in neurofibromatosis 1. ( Cohen, BH; Gupta, A; Packer, RJ; Phillips, PC; Ruggieri, P, 2003) |
| "Thalidomide has been reported to be an effective agent for treatment of chronic graft-versus-host disease (CGVHD)." | 5.08 | Thalidomide as salvage therapy for chronic graft-versus-host disease. ( Blume, KG; Chao, N; Forman, SJ; Kashyap, A; Long, GD; Margolin, K; Molina, A; Nademanee, A; Negrin, RS; Niland, JC; O'Donnell, MR; Parker, PM; Planas, I; Schmidt, GM; Smith, EP; Snyder, DS; Somlo, G; Spielberger, R; Stein, AS; Stepan, DE; Wilsman, K; Zwingenberger, K, 1995) |
| "After decades of disuse because of its teratogenic effects, thalidomide has had a resurgence of use as a promising therapeutic agent for multiple myeloma." | 4.86 | Palliative oncology: thalidomide. ( Prommer, EE, 2010) |
| "Lenalidomide is a potent, novel thalidomide analog that has demonstrated promising clinical activity in patients with relapsed or refractory multiple myeloma (MM)." | 4.84 | Lenalidomide: a new agent for patients with relapsed or refractory multiple myeloma. ( Tariman, JD, 2007) |
| "Lenalidomide and dexamethasone (RD) is a standard of care for relapsed/refractory multiple myeloma (RRMM), but there is limited published data on its efficacy and safety in the "real world" (RW), according to the International Society of Pharmacoeconomics and Outcomes Research definition." | 3.80 | "Real-world" data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group. ( Anagnostopoulos, N; Anargyrou, K; Briasoulis, E; Giannakoulas, N; Hatzimichael, E; Karras, G; Katodritou, E; Kotsopoulou, M; Kyriakou, D; Kyrtsonis, MC; Lalagianni, C; Maniatis, A; Matsouka, P; Michali, E; Papageorgiou, G; Spanoudakis, E; Symeonidis, A; Terpos, E; Tsakiridou, A; Tsionos, K; Vadikolia, C; Zikos, P, 2014) |
| "We here describe a single-institution experience on 40 patients with myelodysplastic syndromes (MDS) consecutively treated with deferasirox at the dose of 10-30 mg/kg/day according to Consensus Guidelines on Iron Chelation Therapy, outside of clinical trials." | 3.78 | Deferasirox treatment for myelodysplastic syndromes: "real-life" efficacy and safety in a single-institution patient population. ( Alimena, G; Breccia, M; Colafigli, G; Federico, V; Finsinger, P; Latagliata, R; Loglisci, G; Petrucci, L; Salaroli, A; Santopietro, M; Serrao, A, 2012) |
| "Factors that affect the response of multiple myeloma patients to thalidomide were evaluated in 40 patients who were not eligible for chemotherapy (untreated: 14, relapse/refractory: 26)." | 3.76 | [Factors affecting the response of thalidomide therapy for patients with multiple myeloma]. ( Agata, M; Ishiyama, M; Kazama, H; Kondo, T; Mori, N; Motoji, T; Oda, T; Okamura, T; Sagawa, K; Sameshima, Y; Shiseki, M; Teramura, M; Yamada, O; Yasunami, T; Yoshinaga, K, 2010) |
| " One patient was treated with lenalidomide (Revlimid) for multiple myeloma, 2 received infliximab, and 1 received etanercept for severe rheumatoid arthritis; the last patient was in a clinical trial of adalimumab for psoriatic arthritis." | 3.73 | Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor alpha inhibitors. ( Badros, A; Deng, A; Gaspari, A; Harvey, V; Junkins-Hopkins, JM; Oghilikhan, M; Samuels, A; Sina, B; Strobel, D, 2006) |
| "To examine dermatologic adverse effects of lenalidomide in patients with amyloidosis and multiple myeloma and to determine whether the adverse effects are different when lenalidomide is used alone compared with when it is used in combination with dexamethasone." | 3.73 | Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma. ( Davis, MD; Dispenzieri, A; Rajkumar, SV; Sviggum, HP, 2006) |
| "We report the dermatologic side effects in 87 patients with multiple myeloma enrolled in a comparative, open-label, clinical trial treated with thalidomide alone (50 patients) or thalidomide and dexamethasone (37 patients)." | 3.72 | Dermatologic side effects of thalidomide in patients with multiple myeloma. ( Bouwhuis, S; El-Azhary, RA; Hall, VC; Rajkumar, SV, 2003) |
| "We report a case of toxic pustuloderma secondary to thalidomide in a patient with severe nodular prurigo." | 3.69 | Thalidomide-induced toxic pustuloderma. ( Basarab, T; Darvay, A; Russell-Jones, R, 1997) |
| "In an open study, oral administration of thalidomide to 7 female patients with classic or definite rheumatoid arthritis, in doses ranging from 6." | 3.67 | Thalidomide. A promising new treatment for rheumatoid arthritis. ( Gutiérrez-Rodríguez, O, 1984) |
| "Sorafenib treatment was effective in two patients who achieved a partial response and a continuous stable disease with duration of 24." | 2.78 | Sorafenib in patients with refractory or recurrent multiple myeloma. ( Goldschmidt, H; Gütgemann, I; Hose, D; Moehler, T; Neben, K; Raab, MS; Schmidt-Wolf, IG; Witzens-Harig, M; Yordanova, A, 2013) |
| "Thalidomide has several mechanisms of action: several immuno-modulatory properties, an anti-angiogenic action and a hypnosedative effect." | 2.43 | [The revival of thalidomide: an old drug with new indications]. ( Laffitte, E, 2006) |
| "Acute generalized exanthematous pustulosis (AGEP) is a diffuse pustular disorder that is primarily drug induced and characterized by acute, extensive, small, nonfollicular, sterile pustules that usually begin in intertriginous folds with widespread edema and erythema." | 1.35 | Acute generalized exanthematous pustulosis: an enigmatic drug-induced reaction. ( Del Rosso, JQ; Michaels, B; Mobini, N; Momin, SB, 2009) |
| "We describe a patient with multiple myeloma who presented with a morbilliform rash induced by thalidomide." | 1.31 | Thalidomide-induced morbilliform rash: diagnosis and continuation of therapy, premedicated with methylprednisolone. ( Lambert, J; Meuleman, L; Nijsten, T; Schroyens, W, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (5.13) | 18.7374 |
| 1990's | 4 (10.26) | 18.2507 |
| 2000's | 14 (35.90) | 29.6817 |
| 2010's | 19 (48.72) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Thieblemont, C | 1 |
| Tilly, H | 1 |
| Gomes da Silva, M | 1 |
| Casasnovas, RO | 1 |
| Fruchart, C | 1 |
| Morschhauser, F | 1 |
| Haioun, C | 1 |
| Lazarovici, J | 1 |
| Grosicka, A | 1 |
| Perrot, A | 1 |
| Trotman, J | 1 |
| Sebban, C | 1 |
| Caballero, D | 1 |
| Greil, R | 2 |
| van Eygen, K | 1 |
| Cohen, AM | 1 |
| Gonzalez, H | 1 |
| Bouabdallah, R | 1 |
| Oberic, L | 1 |
| Corront, B | 1 |
| Choufi, B | 1 |
| Lopez-Guillermo, A | 1 |
| Catalano, J | 1 |
| Van Hoof, A | 1 |
| Briere, J | 1 |
| Cabeçadas, J | 1 |
| Salles, G | 1 |
| Gaulard, P | 1 |
| Bosly, A | 1 |
| Coiffier, B | 1 |
| Kumar, S | 1 |
| Moreau, P | 1 |
| Hari, P | 1 |
| Mateos, MV | 1 |
| Ludwig, H | 1 |
| Shustik, C | 1 |
| Masszi, T | 1 |
| Spencer, A | 1 |
| Hájek, R | 1 |
| Romeril, K | 1 |
| Avivi, I | 1 |
| Liberati, AM | 1 |
| Minnema, MC | 2 |
| Einsele, H | 1 |
| Lonial, S | 1 |
| Berg, D | 1 |
| Lin, J | 1 |
| Gupta, N | 1 |
| Esseltine, DL | 1 |
| Richardson, PG | 1 |
| Egle, A | 1 |
| Steurer, M | 1 |
| Melchardt, T | 1 |
| Weiss, L | 1 |
| Gassner, FJ | 1 |
| Zaborsky, N | 1 |
| Geisberger, R | 1 |
| Catakovic, K | 1 |
| Hartmann, TN | 1 |
| Pleyer, L | 1 |
| Voskova, D | 1 |
| Thaler, J | 1 |
| Lang, A | 1 |
| Girschikofsky, M | 1 |
| Petzer, A | 1 |
| McCarthy, S | 1 |
| Heffron, CCBB | 1 |
| Murphy, M | 1 |
| Yordanova, A | 1 |
| Hose, D | 1 |
| Neben, K | 1 |
| Witzens-Harig, M | 1 |
| Gütgemann, I | 1 |
| Raab, MS | 1 |
| Moehler, T | 1 |
| Goldschmidt, H | 1 |
| Schmidt-Wolf, IG | 1 |
| Hitz, F | 1 |
| Fischer, N | 1 |
| Pabst, T | 1 |
| Caspar, C | 1 |
| Berthod, G | 1 |
| Eckhardt, K | 1 |
| Berardi Vilei, S | 1 |
| Zucca, E | 1 |
| Mey, U | 1 |
| Katodritou, E | 1 |
| Vadikolia, C | 1 |
| Lalagianni, C | 1 |
| Kotsopoulou, M | 1 |
| Papageorgiou, G | 1 |
| Kyrtsonis, MC | 1 |
| Matsouka, P | 1 |
| Giannakoulas, N | 1 |
| Kyriakou, D | 1 |
| Karras, G | 1 |
| Anagnostopoulos, N | 1 |
| Michali, E | 1 |
| Briasoulis, E | 1 |
| Hatzimichael, E | 1 |
| Spanoudakis, E | 1 |
| Zikos, P | 1 |
| Tsakiridou, A | 1 |
| Tsionos, K | 1 |
| Anargyrou, K | 1 |
| Symeonidis, A | 1 |
| Maniatis, A | 1 |
| Terpos, E | 1 |
| Escudero-Vilaplana, V | 1 |
| Osorio Prendes, S | 1 |
| Sanjurjo Sáez, M | 1 |
| Kuiper, EM | 1 |
| Kardaun, SH | 1 |
| Momin, SB | 1 |
| Del Rosso, JQ | 1 |
| Michaels, B | 1 |
| Mobini, N | 1 |
| Prommer, EE | 1 |
| Agata, M | 1 |
| Sameshima, Y | 1 |
| Oda, T | 1 |
| Kondo, T | 1 |
| Ishiyama, M | 1 |
| Yasunami, T | 1 |
| Kazama, H | 1 |
| Okamura, T | 1 |
| Yoshinaga, K | 1 |
| Shiseki, M | 1 |
| Mori, N | 1 |
| Yamada, O | 1 |
| Sagawa, K | 1 |
| Teramura, M | 1 |
| Motoji, T | 1 |
| Eve, HE | 1 |
| Rule, SA | 1 |
| Ch'ang, HJ | 1 |
| Hsu, C | 1 |
| Chen, CH | 1 |
| Chang, YH | 1 |
| Chang, JS | 1 |
| Chen, LT | 1 |
| Grape, J | 1 |
| Frosch, P | 1 |
| Kneppers, E | 1 |
| van der Holt, B | 1 |
| Kersten, MJ | 1 |
| Zweegman, S | 1 |
| Meijer, E | 1 |
| Huls, G | 1 |
| Cornelissen, JJ | 1 |
| Janssen, JJ | 1 |
| Huisman, C | 1 |
| Cornelisse, PB | 1 |
| Bruijnen, CP | 1 |
| Emmelot, M | 1 |
| Sonneveld, P | 1 |
| Lokhorst, HM | 1 |
| Mutis, T | 1 |
| Kuohung, V | 1 |
| Goldberg, LJ | 1 |
| Demierre, MF | 1 |
| Penna, G | 1 |
| Allegra, A | 1 |
| Romeo, G | 1 |
| Alonci, A | 1 |
| Cannavò, A | 1 |
| Russo, S | 1 |
| D'Angelo, A | 1 |
| Petrungaro, A | 1 |
| Musolino, C | 1 |
| Siniscalchi, A | 1 |
| Tendas, A | 1 |
| Morino, L | 1 |
| Dentamaro, T | 1 |
| De Bellis, A | 1 |
| Perrotti, A | 1 |
| de Fabritiis, P | 1 |
| Musto, P | 1 |
| Caravita, T | 1 |
| Breccia, M | 1 |
| Finsinger, P | 1 |
| Loglisci, G | 1 |
| Federico, V | 1 |
| Santopietro, M | 1 |
| Colafigli, G | 1 |
| Petrucci, L | 1 |
| Salaroli, A | 1 |
| Serrao, A | 1 |
| Latagliata, R | 1 |
| Alimena, G | 1 |
| Bohmeyer, J | 1 |
| Achenbach, A | 1 |
| Westenberger, M | 1 |
| Stadler, R | 1 |
| Gupta, A | 1 |
| Cohen, BH | 1 |
| Ruggieri, P | 1 |
| Packer, RJ | 1 |
| Phillips, PC | 1 |
| Remlinger, KA | 1 |
| Hall, VC | 1 |
| El-Azhary, RA | 1 |
| Bouwhuis, S | 1 |
| Rajkumar, SV | 2 |
| Dobson, CM | 1 |
| Parslew, RA | 1 |
| Dimopoulos, MA | 1 |
| Eleutherakis-Papaiakovou, V | 1 |
| Deng, A | 1 |
| Harvey, V | 1 |
| Sina, B | 1 |
| Strobel, D | 1 |
| Badros, A | 1 |
| Junkins-Hopkins, JM | 1 |
| Samuels, A | 1 |
| Oghilikhan, M | 1 |
| Gaspari, A | 1 |
| Varma, K | 1 |
| Finlay, AY | 1 |
| Sviggum, HP | 1 |
| Davis, MD | 1 |
| Dispenzieri, A | 1 |
| Laffitte, E | 1 |
| Tariman, JD | 1 |
| Gutiérrez-Rodríguez, O | 1 |
| Parker, PM | 1 |
| Chao, N | 1 |
| Nademanee, A | 1 |
| O'Donnell, MR | 1 |
| Schmidt, GM | 1 |
| Snyder, DS | 1 |
| Stein, AS | 1 |
| Smith, EP | 1 |
| Molina, A | 1 |
| Stepan, DE | 1 |
| Kashyap, A | 1 |
| Planas, I | 1 |
| Spielberger, R | 1 |
| Somlo, G | 1 |
| Margolin, K | 1 |
| Zwingenberger, K | 1 |
| Wilsman, K | 1 |
| Negrin, RS | 1 |
| Long, GD | 1 |
| Niland, JC | 1 |
| Blume, KG | 1 |
| Forman, SJ | 1 |
| Bielsa, I | 1 |
| Teixidó, J | 1 |
| Ribera, M | 1 |
| Ferrándiz, C | 1 |
| Darvay, A | 1 |
| Basarab, T | 1 |
| Russell-Jones, R | 1 |
| Rúa-Figueroa, I | 1 |
| Erausquin, C | 1 |
| Naranjo, A | 1 |
| Carretero-Hernández, G | 1 |
| Rodriguez-Lozano, C | 1 |
| De la Rosa, P | 1 |
| Nijsten, T | 1 |
| Meuleman, L | 1 |
| Schroyens, W | 1 |
| Lambert, J | 1 |
| Salafia, A | 1 |
| Kharkar, RD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Fludarabine/Rituximab Combined With Escalating Doses of Lenalidomide Followed by Rituximab/Lenalidomide in Untreated Chronic Lymphocytic Leukemia (CLL) - a Dose-finding Study With Concomitant Evaluation of Safety and Efficacy.[NCT00738829] | Phase 1/Phase 2 | 45 participants (Actual) | Interventional | 2008-10-31 | Completed | ||
| Rituximab, Bendamustine and Lenalidomide in Patients With Aggressive B-cell Lymphoma Not Eligible for High Dose Chemotherapy or Anthracycline-Based Therapy. A Phase I/II Trial.[NCT00987493] | Phase 1/Phase 2 | 49 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| A Pilot Clinical and Mechanistic Study of Radiotherapy Plus Thalidomide in Locally Advanced Hepatocellular Carcinoma[NCT00155272] | Phase 1/Phase 2 | 19 participants | Interventional | 2005-03-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for thalidomide and Dermatitis Medicamentosa
| Article | Year |
|---|---|
Palliative oncology: thalidomide.
Topics: Angiogenesis Inhibitors; Constipation; Cytokines; Drug Eruptions; Humans; Hydrolysis; Hypotension, O | 2010 |
Cutaneous reactions to chemotherapy drugs: the art of consultation.
Topics: Animals; Antineoplastic Agents; Bleomycin; Docetaxel; Doxorubicin; Drug Eruptions; Humans; Hydroxyur | 2003 |
Adverse effects of thalidomide administration in patients with neoplastic diseases.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antineoplastic Agents; Clinical Trials, Phase II | 2004 |
[The revival of thalidomide: an old drug with new indications].
Topics: Angiogenesis Inhibitors; Drug Eruptions; Humans; Leprostatic Agents; Peripheral Nervous System Disea | 2006 |
Lenalidomide: a new agent for patients with relapsed or refractory multiple myeloma.
Topics: Anorexia; Antineoplastic Agents; Apoptosis; Constipation; Diarrhea; Drug Eruptions; Drug Monitoring; | 2007 |
9 trials available for thalidomide and Dermatitis Medicamentosa
| Article | Year |
|---|---|
Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2017 |
Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2017 |
Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CD4-Positive T-Lymphocytes; Consolidati | 2018 |
Sorafenib in patients with refractory or recurrent multiple myeloma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2013 |
Rituximab, bendamustine, and lenalidomide in patients with aggressive B cell lymphoma not eligible for high-dose chemotherapy or anthracycline-based therapy: phase I results of the SAKK 38/08 trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2013 |
Phase II study of concomitant thalidomide during radiotherapy for hepatocellular carcinoma.
Topics: Aged; Analysis of Variance; Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Chemokine | 2012 |
Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial.
Topics: Acute Disease; Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Cyclophosphamide; Cycl | 2011 |
Phase I study of thalidomide for the treatment of plexiform neurofibroma in neurofibromatosis 1.
Topics: Adolescent; Adult; Angiogenesis Inhibitors; Child; Cohort Studies; Dermatologic Agents; Dose-Respons | 2003 |
Thalidomide as salvage therapy for chronic graft-versus-host disease.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Child; Chronic Disease; Constipation; Cyclosporine; | 1995 |
25 other studies available for thalidomide and Dermatitis Medicamentosa
| Article | Year |
|---|---|
Lentigines within fixed drug eruption: reply to 'Multiple lentigines arising on resolving psoriatic plaques after treatment with apremilast'.
Topics: Adult; Dermoscopy; Drug Eruptions; Exanthema; Female; Humans; Hyperpigmentation; Inflammation; Lenti | 2019 |
"Real-world" data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group.
Topics: Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dex | 2014 |
[Suspected itchy rash secondary to lenalidomide].
Topics: Aged; Angiogenesis Inhibitors; Anti-Inflammatory Agents; Drug Eruptions; Exanthema; Female; Humans; | 2014 |
Late onset perforating folliculitis induced by lenalidomide: a case report.
Topics: Drug Eruptions; Folliculitis; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Thalidom | 2015 |
Acute generalized exanthematous pustulosis: an enigmatic drug-induced reaction.
Topics: Acute Disease; Aged; Dexamethasone; Diagnosis, Differential; Drug Eruptions; Exanthema; Humans; Male | 2009 |
[Factors affecting the response of thalidomide therapy for patients with multiple myeloma].
Topics: Adult; Aged; Aged, 80 and over; Constipation; Dexamethasone; Disease-Free Survival; Drug Eruptions; | 2010 |
Lenalidomide-induced tumour flare reaction in mantle cell lymphoma.
Topics: Antineoplastic Agents; Drug Eruptions; Fatal Outcome; Female; Humans; Lenalidomide; Leukocytosis; Ly | 2010 |
[Papular drug eruption along the lines of Blaschko caused by lenalidomide].
Topics: Antineoplastic Agents; Diagnosis, Differential; Drug Eruptions; Humans; Leg Dermatoses; Lenalidomide | 2011 |
Lenalidomide-induced purpuric eruption: a new adverse cutaneous reaction.
Topics: Aged; Amyloidosis; Antineoplastic Agents; Drug Eruptions; Humans; Lenalidomide; Male; Purpura; Thali | 2011 |
Severe dermatologic adverse reactions after exposure to lenalidomide in multiple myeloma patients with a positive HLA-DRB1*1501 and HLA-DQB1*0602.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Agents; Dexamethasone; Drug Eruptions; Femal | 2012 |
Lenalidomide cutaneous adverse event: a case of Stevens-Johnson syndrome (SJS) in a primary plasma cell leukaemia patient treated with lenalidomide and dexamethasone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Eruptions; Humans; Lenalidomide; | 2012 |
Deferasirox treatment for myelodysplastic syndromes: "real-life" efficacy and safety in a single-institution patient population.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites; Azacitidine; Benzoates; Chelating Agents; Deferasir | 2012 |
[Thalidomide therapy of cutaneous lupus erythematosus].
Topics: Adult; Drug Eruptions; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Intrader | 2002 |
Dermatologic side effects of thalidomide in patients with multiple myeloma.
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug | 2003 |
Exacerbation of psoriasis by thalidomide in Behçet's syndrome.
Topics: Behcet Syndrome; Drug Eruptions; Female; Humans; Immunosuppressive Agents; Middle Aged; Psoriasis; T | 2003 |
Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor alpha inhibitors.
Topics: Adalimumab; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Ag | 2006 |
Exacerbation of psoriasis by thalidomide in a patient with erythema multiforme.
Topics: Adult; Drug Eruptions; Erythema Multiforme; Female; Humans; Immunosuppressive Agents; Psoriasis; Tha | 2006 |
[Potential side effects of thalidomide].
Topics: Constipation; Disorders of Excessive Somnolence; Drug Eruptions; Humans; Immunosuppressive Agents; L | 2006 |
Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma.
Topics: Amyloidosis; Anti-Inflammatory Agents; Clinical Trials as Topic; Dexamethasone; Drug Eruptions; Drug | 2006 |
Thalidomide. A promising new treatment for rheumatoid arthritis.
Topics: Adult; Arthritis, Rheumatoid; Blood Sedimentation; Drug Eruptions; Female; Humans; Leukopenia; Middl | 1984 |
Erythroderma due to thalidomide: report of two cases.
Topics: Adult; Dermatitis, Exfoliative; Drug Eruptions; Eosinophilia; Female; Humans; Kidney Failure, Chroni | 1994 |
Thalidomide-induced toxic pustuloderma.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Dermatitis, Exfoliative; Drug Eruptions; Female; Hum | 1997 |
Pustuloderma during cutaneous lupus treatment with thalidomide.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Dermatologic Agents; Drug Eruptions; Female; Humans; | 1999 |
Thalidomide-induced morbilliform rash: diagnosis and continuation of therapy, premedicated with methylprednisolone.
Topics: Aged; Anti-Inflammatory Agents; Drug Eruptions; Humans; Immunosuppressive Agents; Male; Methylpredni | 2002 |
Thalidomide and exfoliative dermatitis.
Topics: Drug Eruptions; Erythema Nodosum; Humans; Leprosy, Lepromatous; Male; Middle Aged; Thalidomide | 1988 |